Cargando…
Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation
BACKGROUND: There is an urgent need for developing objective, effective and convenient measurements to help clinicians accurately identify bradykinesia. The purpose of this study is to evaluate the accuracy of an objective approach assessing bradykinesia in finger tapping (FT) that uses evolutionary...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094893/ https://www.ncbi.nlm.nih.gov/pubmed/30147869 http://dx.doi.org/10.1186/s40035-018-0124-x |
_version_ | 1783347883887558656 |
---|---|
author | Gao, Chao Smith, Stephen Lones, Michael Jamieson, Stuart Alty, Jane Cosgrove, Jeremy Zhang, Pingchen Liu, Jin Chen, Yimeng Du, Juanjuan Cui, Shishuang Zhou, Haiyan Chen, Shengdi |
author_facet | Gao, Chao Smith, Stephen Lones, Michael Jamieson, Stuart Alty, Jane Cosgrove, Jeremy Zhang, Pingchen Liu, Jin Chen, Yimeng Du, Juanjuan Cui, Shishuang Zhou, Haiyan Chen, Shengdi |
author_sort | Gao, Chao |
collection | PubMed |
description | BACKGROUND: There is an urgent need for developing objective, effective and convenient measurements to help clinicians accurately identify bradykinesia. The purpose of this study is to evaluate the accuracy of an objective approach assessing bradykinesia in finger tapping (FT) that uses evolutionary algorithms (EAs) and explore whether it can be used to identify early stage Parkinson’s disease (PD). METHODS: One hundred and seven PD, 41 essential tremor (ET) patients and 49 normal controls (NC) were recruited. Participants performed a standard FT task with two electromagnetic tracking sensors attached to the thumb and index finger. Readings from the sensors were transmitted to a tablet computer and subsequently analyzed by using EAs. The output from the device (referred to as "PD-Monitor") scaled from − 1 to + 1 (where higher scores indicate greater severity of bradykinesia). Meanwhile, the bradykinesia was rated clinically using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) FT item. RESULTS: With an increasing MDS-UPDRS FT score, the PD-Monitor score from the same hand side increased correspondingly. PD-Monitor score correlated well with MDS-UPDRS FT score (right side: r = 0.819, P = 0.000; left side: r = 0.783, P = 0.000). Moreover, PD-Monitor scores in 97 PD patients with MDS-UPDRS FT bradykinesia and each PD subgroup (FT bradykinesia scored from 1 to 3) were all higher than that in NC. Receiver operating characteristic (ROC) curves revealed that PD-Monitor FT scores could detect different severity of bradykinesia with high accuracy (≥89.7%) in the right dominant hand. Furthermore, PD-Monitor scores could discriminate early stage PD from NC, with area under the ROC curve greater than or equal to 0.899. Additionally, ET without bradykinesia could be differentiated from PD by PD-Monitor scores. A positive correlation of PD-Monitor scores with modified Hoehn and Yahr stage was found in the left hand sides. CONCLUSIONS: Our study demonstrated that a simple to use device employing classifiers derived from EAs could not only be used to accurately measure different severity of bradykinesia in PD, but also had the potential to differentiate early stage PD from normality. |
format | Online Article Text |
id | pubmed-6094893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60948932018-08-24 Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation Gao, Chao Smith, Stephen Lones, Michael Jamieson, Stuart Alty, Jane Cosgrove, Jeremy Zhang, Pingchen Liu, Jin Chen, Yimeng Du, Juanjuan Cui, Shishuang Zhou, Haiyan Chen, Shengdi Transl Neurodegener Research BACKGROUND: There is an urgent need for developing objective, effective and convenient measurements to help clinicians accurately identify bradykinesia. The purpose of this study is to evaluate the accuracy of an objective approach assessing bradykinesia in finger tapping (FT) that uses evolutionary algorithms (EAs) and explore whether it can be used to identify early stage Parkinson’s disease (PD). METHODS: One hundred and seven PD, 41 essential tremor (ET) patients and 49 normal controls (NC) were recruited. Participants performed a standard FT task with two electromagnetic tracking sensors attached to the thumb and index finger. Readings from the sensors were transmitted to a tablet computer and subsequently analyzed by using EAs. The output from the device (referred to as "PD-Monitor") scaled from − 1 to + 1 (where higher scores indicate greater severity of bradykinesia). Meanwhile, the bradykinesia was rated clinically using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) FT item. RESULTS: With an increasing MDS-UPDRS FT score, the PD-Monitor score from the same hand side increased correspondingly. PD-Monitor score correlated well with MDS-UPDRS FT score (right side: r = 0.819, P = 0.000; left side: r = 0.783, P = 0.000). Moreover, PD-Monitor scores in 97 PD patients with MDS-UPDRS FT bradykinesia and each PD subgroup (FT bradykinesia scored from 1 to 3) were all higher than that in NC. Receiver operating characteristic (ROC) curves revealed that PD-Monitor FT scores could detect different severity of bradykinesia with high accuracy (≥89.7%) in the right dominant hand. Furthermore, PD-Monitor scores could discriminate early stage PD from NC, with area under the ROC curve greater than or equal to 0.899. Additionally, ET without bradykinesia could be differentiated from PD by PD-Monitor scores. A positive correlation of PD-Monitor scores with modified Hoehn and Yahr stage was found in the left hand sides. CONCLUSIONS: Our study demonstrated that a simple to use device employing classifiers derived from EAs could not only be used to accurately measure different severity of bradykinesia in PD, but also had the potential to differentiate early stage PD from normality. BioMed Central 2018-08-16 /pmc/articles/PMC6094893/ /pubmed/30147869 http://dx.doi.org/10.1186/s40035-018-0124-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gao, Chao Smith, Stephen Lones, Michael Jamieson, Stuart Alty, Jane Cosgrove, Jeremy Zhang, Pingchen Liu, Jin Chen, Yimeng Du, Juanjuan Cui, Shishuang Zhou, Haiyan Chen, Shengdi Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title | Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title_full | Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title_fullStr | Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title_full_unstemmed | Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title_short | Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms: clinical validation |
title_sort | objective assessment of bradykinesia in parkinson’s disease using evolutionary algorithms: clinical validation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094893/ https://www.ncbi.nlm.nih.gov/pubmed/30147869 http://dx.doi.org/10.1186/s40035-018-0124-x |
work_keys_str_mv | AT gaochao objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT smithstephen objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT lonesmichael objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT jamiesonstuart objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT altyjane objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT cosgrovejeremy objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT zhangpingchen objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT liujin objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT chenyimeng objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT dujuanjuan objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT cuishishuang objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT zhouhaiyan objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation AT chenshengdi objectiveassessmentofbradykinesiainparkinsonsdiseaseusingevolutionaryalgorithmsclinicalvalidation |